Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 1
1993 1
1994 1
1995 4
1996 16
1997 11
1998 13
1999 7
2000 13
2001 7
2002 7
2003 9
2004 9
2005 7
2006 5
2007 1
2008 9
2009 10
2010 7
2011 9
2012 11
2013 2
2014 4
2015 5
2016 3
2017 4
2018 2
2019 9
2020 11
2021 13
2022 9
2023 9
2024 6
2025 10
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Results by year

Filters applied: . Clear all
Page 1
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P, Shi L, Huang W, Shao ZM. Jiang YZ, et al. Among authors: verschraegen c. Cancer Cell. 2019 Mar 18;35(3):428-440.e5. doi: 10.1016/j.ccell.2019.02.001. Epub 2019 Mar 7. Cancer Cell. 2019. PMID: 30853353 Free article.
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.
Jiang YZ, Ma D, Jin X, Xiao Y, Yu Y, Shi J, Zhou YF, Fu T, Lin CJ, Dai LJ, Liu CL, Zhao S, Su GH, Hou W, Liu Y, Chen Q, Yang J, Zhang N, Zhang WJ, Liu W, Ge W, Yang WT, You C, Gu Y, Kaklamani V, Bertucci F, Verschraegen C, Daemen A, Shah NM, Wang T, Guo T, Shi L, Perou CM, Zheng Y, Huang W, Shao ZM. Jiang YZ, et al. Among authors: verschraegen c. Nat Cancer. 2024 Apr;5(4):673-690. doi: 10.1038/s43018-024-00725-0. Epub 2024 Feb 12. Nat Cancer. 2024. PMID: 38347143
TLK-286.
Verschraegen CF, Smith HO, Lee FC, Cathcart C, Norenberg JP. Verschraegen CF, et al. IDrugs. 2004 Aug;7(8):771-81. IDrugs. 2004. PMID: 15334311 Review.
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, Verschraegen C, Stover DG, Kaklamani V, Wang ZH, Shao ZM. Jiang YZ, et al. Among authors: verschraegen c. Cell Res. 2021 Feb;31(2):178-186. doi: 10.1038/s41422-020-0375-9. Epub 2020 Jul 27. Cell Res. 2021. PMID: 32719455 Free PMC article. Clinical Trial.
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss J, Hava DL, Janku F. Luke JJ, et al. Among authors: verschraegen cf. Clin Cancer Res. 2023 Jul 5;29(13):2435-2444. doi: 10.1158/1078-0432.CCR-23-0118. Clin Cancer Res. 2023. PMID: 37227176 Free PMC article. Clinical Trial.
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Kim S, et al. Among authors: verschraegen c. Lancet. 2022 Sep 24;400(10357):1008-1019. doi: 10.1016/S0140-6736(22)01659-2. Epub 2022 Sep 12. Lancet. 2022. PMID: 36108657 Free PMC article. Clinical Trial.
Benchmarks for Academic Oncology Faculty.
Anthony L, Atweh G, Bhatia R, Carey LA, Chang JC, Edelman MJ, Kantoff PW, Markham MJ, Messersmith W, Nelson EL, Oettel K, O'Regan R, Verschraegen CF, Vose JM. Anthony L, et al. Among authors: verschraegen cf. JCO Oncol Pract. 2021 Mar;17(3):e440-e444. doi: 10.1200/OP.20.00020. Epub 2020 Sep 30. JCO Oncol Pract. 2021. PMID: 32997608 Free PMC article. Review.
Tasidotin HCl (Genzyme).
Rasila KK, Verschraegen C. Rasila KK, et al. Among authors: verschraegen c. Curr Opin Investig Drugs. 2005 Jun;6(6):631-8. Curr Opin Investig Drugs. 2005. PMID: 15988915 Review. No abstract available.
ET-743 (PharmaMar/NCI/Ortho Biotech).
Verschraegen CF, Glover K. Verschraegen CF, et al. Curr Opin Investig Drugs. 2001 Nov;2(11):1631-8. Curr Opin Investig Drugs. 2001. PMID: 11763168 Review.
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Owen DH, Benner B, Wei L, Sukrithan V, Goyal A, Zhou Y, Pilcher C, Suffren SA, Christenson G, Curtis N, Jukich M, Schwarz E, Savardekar H, Norman R, Ferguson S, Kleiber B, Wesolowski R, Carson WE, Otterson GA, Verschraegen CF, Shah MH, Konda B. Owen DH, et al. Among authors: verschraegen cf. Clin Cancer Res. 2023 Feb 16;29(4):731-741. doi: 10.1158/1078-0432.CCR-22-1552. Clin Cancer Res. 2023. PMID: 36255391 Free PMC article.
231 results